close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

186.32 -3.62 (-1.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Ligand Reports Third Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand To Report Third Quarter 2023 Financial Results On November 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
News headline image
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Appoints Martine Zimmermann to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Second Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand To Report Second Quarter 2023 Financial Results On August 8
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
From Novan, Inc.
Via GlobeNewswire
News headline image
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports First Quarter 2023 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Fourth Quarter Financial Results on February 22
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Provides Highlights from its Investor and Analyst Day Event
From Ligand Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today